Literature DB >> 10457048

Design of treatment trials for functional gastrointestinal disorders.

S J Veldhuyzen van Zanten1, N J Talley, P Bytzer, K B Klein, P J Whorwell, A R Zinsmeister.   

Abstract

Until recently many clinical trials of functional gastrointestinal disorders (FGIDs) suffered from important weaknesses in trial design, study execution, and data analysis. This makes it difficult to determine whether truly efficacious therapies exist for these disorders. One of the important methodologic problems is the absence of validated outcome measures and lack of consensus among stakeholders on how to measure outcome. Currently much of the effort is being put into the development of validated outcome measures for several of the FGIDs. The randomized, controlled trial with parallel groups is the design of choice. In this report, guidelines are given for the basic architecture of intervention studies of FGIDs. Further studies on design issues are required to ensure the recommendations will become evidence based in the future.

Entities:  

Mesh:

Year:  1999        PMID: 10457048      PMCID: PMC1766689          DOI: 10.1136/gut.45.2008.ii69

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  30 in total

1.  The Glasgow Dyspepsia Severity Score--a tool for the global measurement of dyspepsia.

Authors:  E M el-Omar; S Banerjee; A Wirz; K E McColl
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-10       Impact factor: 2.566

Review 2.  AGA technical review: evaluation of dyspepsia. American Gastroenterological Association.

Authors:  N J Talley; M D Silverstein; L Agréus; O Nyrén; A Sonnenberg; G Holtmann
Journal:  Gastroenterology       Date:  1998-03       Impact factor: 22.682

3.  Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials.

Authors:  S J Veldhuyzen van Zanten; C Cleary; N J Talley; T C Peterson; O Nyrén; L A Bradley; M Verlinden; G N Tytgat
Journal:  Am J Gastroenterol       Date:  1996-04       Impact factor: 10.864

4.  Improving the quality of reporting of randomized controlled trials. The CONSORT statement.

Authors:  C Begg; M Cho; S Eastwood; R Horton; D Moher; I Olkin; R Pitkin; D Rennie; K F Schulz; D Simel; D F Stroup
Journal:  JAMA       Date:  1996-08-28       Impact factor: 56.272

5.  Symptomatology, quality of life and economic features of irritable bowel syndrome--the effect of hypnotherapy.

Authors:  L A Houghton; D J Heyman; P J Whorwell
Journal:  Aliment Pharmacol Ther       Date:  1996-02       Impact factor: 8.171

6.  Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome.

Authors:  B A Hahn; L J Kirchdoerfer; S Fullerton; E Mayer
Journal:  Aliment Pharmacol Ther       Date:  1997-06       Impact factor: 8.171

7.  Quality of life in persons with irritable bowel syndrome: development and validation of a new measure.

Authors:  D L Patrick; D A Drossman; I O Frederick; J DiCesare; K L Puder
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

8.  Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy.

Authors:  N J Talley; A L Weaver; D L Tesmer; A R Zinsmeister
Journal:  Gastroenterology       Date:  1993-11       Impact factor: 22.682

Review 9.  Measuring health-related quality of life.

Authors:  G H Guyatt; D H Feeny; D L Patrick
Journal:  Ann Intern Med       Date:  1993-04-15       Impact factor: 25.391

10.  Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer.

Authors:  E Dimenäs; H Glise; B Hallerbäck; H Hernqvist; J Svedlund; I Wiklund
Journal:  Scand J Gastroenterol       Date:  1995-11       Impact factor: 2.423

View more
  25 in total

1.  Chronic Functional Abdominal Pain (CFAP).

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-08

2.  Treatment effects of partially hydrolyzed guar gum on symptoms and quality of life of patients with irritable bowel syndrome. A multicenter randomized open trial.

Authors:  Giancarlo Parisi; Enrico Bottona; Maurizio Carrara; Fabrizio Cardin; Alessandra Faedo; Dario Goldin; Marco Marino; Maurizio Pantalena; Gianni Tafner; Giorgio Verdianelli; Maurizio Zilli; Gioacchino Leandro
Journal:  Dig Dis Sci       Date:  2005-06       Impact factor: 3.199

3.  Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics.

Authors:  Nicholas J Talley; G Richard Locke; Linda M Herrick; Vickie M Silvernail; Charlene M Prather; Brian E Lacy; John K DiBaise; Colin W Howden; Darren M Brenner; Ernest P Bouras; Hashem B El-Serag; Bincy P Abraham; Paul Moayyedi; Alan R Zinsmeister
Journal:  Contemp Clin Trials       Date:  2012-02-10       Impact factor: 2.226

Review 4.  Irritable bowel syndrome: new agents targeting serotonin receptor subtypes.

Authors:  F De Ponti; M Tonini
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Assessment of abdominal pain through global outcomes and recent FDA recommendations in children: are we ready for change?

Authors:  Saeed Mohammad; Carlo Di Lorenzo; Nader N Youssef; Adrian Miranda; Samuel Nurko; Paul Hyman; Miguel Saps
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-01       Impact factor: 2.839

6.  Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis.

Authors:  Ji Yong Ahn; Kyung Hun Lee; Chang Hwan Choi; Ju Wan Kim; Hyun Woong Lee; Jeong Wook Kim; Mi Kyung Kim; Gui Young Kwon; Seungbong Han; Seong-Eun Kim; Sung Min Kim; Sae Kyung Chang
Journal:  Dig Dis Sci       Date:  2013-11-27       Impact factor: 3.199

Review 7.  Benefit-risk assessment of tegaserod in irritable bowel syndrome.

Authors:  Richard Lea; Peter J Whorwell
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

8.  Validation of irritable bowel syndrome Global Improvement Scale: an integrated symptom end point for assessing treatment efficacy.

Authors:  Susan Gordon; Vanessa Ameen; Barbara Bagby; Britt Shahan; Priti Jhingran; Eric Carter
Journal:  Dig Dis Sci       Date:  2003-07       Impact factor: 3.199

9.  A randomized controlled trial of imipramine in patients with irritable bowel syndrome.

Authors:  Heitham Abdul-Baki; Ihab I El Hajj; Lara Elzahabi; Cecilio Azar; Elie Aoun; Assaad Skoury; Hani Chaar; Ala I Sharara
Journal:  World J Gastroenterol       Date:  2009-08-07       Impact factor: 5.742

10.  Altered Colonic Bacterial Fermentation as a Potential Pathophysiological Factor in Irritable Bowel Syndrome.

Authors:  Tamar Ringel-Kulka; Chang Hwan Choi; Daniel Temas; Ari Kim; Daniele M Maier; Karen Scott; Joseph A Galanko; Yehuda Ringel
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.